{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:22:29Z","timestamp":1780428149359,"version":"3.54.1"},"reference-count":19,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T00:00:00Z","timestamp":1533340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1133479"],"award-info":[{"award-number":["APP1133479"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1139902"],"award-info":[{"award-number":["APP1139902"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2018,12]]},"abstract":"Abstract<\/jats:title>Dapsone may be used for Pneumocystis jirovecii<\/jats:italic> pneumonia (PJP<\/jats:styled-content>) prophylaxis in hematology patients receiving immunosuppressive therapy or after hematopoietic stem cell transplant (HSCT<\/jats:styled-content>) in the setting of trimethoprim\u2010sulfamethoxazole (TMP<\/jats:styled-content>\u2010SMX<\/jats:styled-content>) adverse drug reaction (ADR<\/jats:styled-content>) history. Dapsone\u2010induced hematological toxicities such as oxidative hemolysis may limit use in these patients and modern assessments of dapsone allergy cross\u2010reactivity in non\u2010HIV<\/jats:styled-content> patients with a sulfonamide allergy are largely absent. The aim of this single\u2010centre, retrospective study was to describe dapsone usage in hematology patients requiring PJP<\/jats:styled-content> prophylaxis, including HSCT<\/jats:styled-content> recipients, over a 12\u2010month period in terms of indications, incidence of dapsone\u2010attributed oxidative hemolysis, and immune cross\u2010reactivity in those previously labeled with a sulfonamide allergy, as well as describing potential opportunities for first\u2010line TMP<\/jats:styled-content>\u2010SMX PJP<\/jats:styled-content> prophylaxis reintroduction. Of 24 patients meeting the study inclusion criteria, 12 (50%) were receiving dapsone PJP<\/jats:styled-content> prophylaxis post\u2010HSCT<\/jats:styled-content>. No cases of breakthrough PJP<\/jats:styled-content> infection were noted. Sixteen patients (67%) were initiated on dapsone to avoid the perceived risk of further myelosuppression with TMP<\/jats:styled-content>\u2010SMX<\/jats:styled-content> and five patients (21%) because of prior delayed immune\u2010mediated allergy to TMP<\/jats:styled-content>\u2010SMX<\/jats:styled-content>. None experienced rash with dapsone therapy. Six patients (25%) were successfully rechallenged on TMP<\/jats:styled-content>\u2010SMX<\/jats:styled-content>, including one patient with prior TMP<\/jats:styled-content>\u2010SMX<\/jats:styled-content>\u2010associated rash. Four (17%) patients had confirmed oxidative hemolysis, all resulting in dapsone cessation. Dapsone PJP<\/jats:styled-content> prophylaxis in hematology patients was effective and safe, with nonlife threatening dapsone\u2010related hemolysis noted in a small number. An absence of sulfonamide allergy cross\u2010reactivity was noted, suggesting greater TMP<\/jats:styled-content>\u2010SMX<\/jats:styled-content> rechallenges or desensitization could be considered in those receiving dapsone.<\/jats:p>","DOI":"10.1111\/tid.12968","type":"journal-article","created":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T08:12:56Z","timestamp":1532160776000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii<\/i> pneumonia prophylaxis in hematology malignancy and transplant recipients"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-578X","authenticated-orcid":false,"given":"Karen F.","family":"Urbancic","sequence":"first","affiliation":[{"name":"Pharmacy Department Austin Health Heidelberg Victoria Australia"},{"name":"Infectious Diseases Department and Centre for Antibiotic Allergy and Research Austin Health Heidelberg Victoria Australia"},{"name":"Department of Oncology National Centre for Infections in Cancer National Health and Medical Research Council Centre of Research Excellence Peter MacCallum Cancer Centre University of Melbourne Parkville Victoria Australia"},{"name":"Department of Medicine University of Melbourne Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Pisasale","sequence":"additional","affiliation":[{"name":"Pharmacy Department Austin Health Heidelberg Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Wight","sequence":"additional","affiliation":[{"name":"Clinical Haematology Department Austin Health Heidelberg Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5111-6367","authenticated-orcid":false,"given":"Jason A.","family":"Trubiano","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department and Centre for Antibiotic Allergy and Research Austin Health Heidelberg Victoria Australia"},{"name":"Department of Oncology National Centre for Infections in Cancer National Health and Medical Research Council Centre of Research Excellence Peter MacCallum Cancer Centre University of Melbourne Parkville Victoria Australia"},{"name":"Department of Medicine University of Melbourne Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,8,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12599"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw157"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)00008-3"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199301000-00010"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199303000-00008"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/514626"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.114733"},{"key":"e_1_2_6_9_1","volume-title":"Textbook of Adverse Drug Reactions","author":"Rawlins MD","year":"1977"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14498"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.83"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12161"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2008.12.005"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1976.tb130355.x"},{"key":"e_1_2_6_15_1","volume-title":"Therapeutic Guideline: Antibiotic","author":"Antibiotic Expert Group","year":"2014"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/313509"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12201"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.7182\/pit2015153"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.285"},{"key":"e_1_2_6_20_1","first-page":"CD005590","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non\u2010HIV immunocompromised patients","volume":"10","author":"Stern A","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12968","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T02:27:10Z","timestamp":1694744830000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,4]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/tid.12968"],"URL":"https:\/\/doi.org\/10.1111\/tid.12968","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,4]]},"assertion":[{"value":"2018-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12968"}}